Higher Scientific Officer (Target Biology and Genomic Instability)

02/10/2019, 23:55

Sutton
Cancer Therapeutics
Directorate Cancer Therapeutics
Full time
Fixed Term
2 years
35
Expected starting salary circa £32,000
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.

The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

The new team led by Dr Anderson Wang is looking for an experienced Higher Scientific Officer to help their work on genomic instability in cancer. This position is critical for strengthening our drug discovery portfolio and supporting biology teams within the CRUK Cancer Therapeutics Unit in Sutton. 

The post holder is required to have a PhD in a biological science or equivalent experience, and to have extensive experience in tissue culture, cell biology, biochemistry and in particular CRISPR/Cas gene editing technology. Please refer to the attached job description and person-specification for full details. Please note there is also  a Scientific Officer vacancy in the same team (ref 839) which might be of interest to applicants with relevant experience.

This appointment is for two years in the first instance. Salary is based on Higher Scientific Officer Pay Grade which has a salary range of £32,000 rising to £44,400. Progression is determined by annual performance review. Starting salary will be based on previous experience.

We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff.

In partnership with

Cancer Research UK
Additional Documentation for Candidates